Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1), also known as B7-H6, is a ligand for the natural cytotoxicity receptor NKp30 found on natural killer (NK) cells. It is a type I transmembrane protein belonging to the B7 family. Unlike many B7 family members, B7-H6 is not constitutively expressed in normal tissues but is frequently upregulated in tumor cells, making it a potential target for cancer immunotherapy. Upon binding to NKp30, it triggers NK cell activation and promotes the lysis of target cells expressing the ligand.
Binds to NKp30 receptor on NK cells, activating cytotoxic activity against target cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1).